Urinary neutrophil gelatinase-associated lipocalin as a marker for disease activity in lupus nephritis. 2018

Mohamed S El Shahawy, and Mahmoud H Hemida, and Hafez A Abdel-Hafez, and Tarek Z El-Baz, and Abdel-Wahab M Lotfy, and Tarek M Emran
a Department of Internal Medicine, Gastroenterology Unit , AL-Azhar University , Cairo , Egypt.

The neutrophil gelatinase-associated lipocalin (NGAL) has been emerging as a novel biomarker of acute kidney injury while its value in lupus nephritis is uncertain. The aim of this study was to assess urinary NGAL levels as a marker for disease activity in patients with lupus nephritis.This study included 70 systemic lupus erythematosus (SLE) patients; 50 with active lupus nephritis (LN) and 20 without as well as 20 matched controls. The neutrophil gelatinase-associated lipocalin (NGAL) in both serum and urine samples was measured by enzyme-linked immunosorbent assay (ELISA). Patients with active LN received standard treatment then assessed for response as well as the value of urinary NGAL (uNGAL). Our results revealed that, The SLE patients with or without LN had an elevated urinary NGAL as compared to controls (p < 0.000) and the mean of uNGAL was (20.67 ± 5.34),(10.63 ± 3.53),(5.65 ± 2.49) respectively. Furthermore,Urinary NGAL levels in LN patients were significantly higher than those in non-LN patients (P < 0.0001). In the ROC curve analysis , the diagnostic performance of uNGAL for discriminating patients with nephritis from those without nephritis showed that the best cutoff value was 13.66 ng/ml ,sensitivity 92%,specificity 75%,area undercurve (0.959) and (P < 0.0001). Measurement of urinary NGAL levels showed an excellent diagnostic performance for discriminating patients with LN from SLE without nephritis.

UI MeSH Term Description Entries
D008181 Lupus Nephritis Glomerulonephritis associated with autoimmune disease SYSTEMIC LUPUS ERYTHEMATOSUS. Lupus nephritis is histologically classified into 6 classes: class I - normal glomeruli, class II - pure mesangial alterations, class III - focal segmental glomerulonephritis, class IV - diffuse glomerulonephritis, class V - diffuse membranous glomerulonephritis, and class VI - advanced sclerosing glomerulonephritis (The World Health Organization classification 1982). Glomerulonephritis, Lupus,Lupus Glomerulonephritis,Nephritis, Lupus,Glomerulonephritides, Lupus,Lupus Glomerulonephritides,Lupus Nephritides,Nephritides, Lupus
D008297 Male Males
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000071068 Lipocalin-2 A lipocalin of approximately 200 amino acids that functions as an iron transporter and is expressed by cells of BONE MARROW and many other cells with secretory functions. It is involved in APOPTOSIS and may function to limit pathogenic bacterial growth as part of the INNATE IMMUNE RESPONSE. Lipocalin-2 Protein,NGAL Protein,Neutrophil Gelatinase-Associated Lipocalin,Oncogene 24p3 Protein,Siderocalin Protein,Lipocalin 2,Lipocalin 2 Protein,Neutrophil Gelatinase Associated Lipocalin
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D012372 ROC Curve A graphic means for assessing the ability of a screening test to discriminate between healthy and diseased persons; may also be used in other studies, e.g., distinguishing stimuli responses as to a faint stimuli or nonstimuli. ROC Analysis,Receiver Operating Characteristic,Analysis, ROC,Analyses, ROC,Characteristic, Receiver Operating,Characteristics, Receiver Operating,Curve, ROC,Curves, ROC,ROC Analyses,ROC Curves,Receiver Operating Characteristics
D015415 Biomarkers Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, ENVIRONMENTAL EXPOSURE and its effects, disease diagnosis; METABOLIC PROCESSES; SUBSTANCE ABUSE; PREGNANCY; cell line development; EPIDEMIOLOGIC STUDIES; etc. Biochemical Markers,Biological Markers,Biomarker,Clinical Markers,Immunologic Markers,Laboratory Markers,Markers, Biochemical,Markers, Biological,Markers, Clinical,Markers, Immunologic,Markers, Laboratory,Markers, Serum,Markers, Surrogate,Markers, Viral,Serum Markers,Surrogate Markers,Viral Markers,Biochemical Marker,Biologic Marker,Biologic Markers,Clinical Marker,Immune Marker,Immune Markers,Immunologic Marker,Laboratory Marker,Marker, Biochemical,Marker, Biological,Marker, Clinical,Marker, Immunologic,Marker, Laboratory,Marker, Serum,Marker, Surrogate,Serum Marker,Surrogate End Point,Surrogate End Points,Surrogate Endpoint,Surrogate Endpoints,Surrogate Marker,Viral Marker,Biological Marker,End Point, Surrogate,End Points, Surrogate,Endpoint, Surrogate,Endpoints, Surrogate,Marker, Biologic,Marker, Immune,Marker, Viral,Markers, Biologic,Markers, Immune
D016022 Case-Control Studies Comparisons that start with the identification of persons with the disease or outcome of interest and a control (comparison, referent) group without the disease or outcome of interest. The relationship of an attribute is examined by comparing both groups with regard to the frequency or levels of outcome over time. Case-Base Studies,Case-Comparison Studies,Case-Referent Studies,Matched Case-Control Studies,Nested Case-Control Studies,Case Control Studies,Case-Compeer Studies,Case-Referrent Studies,Case Base Studies,Case Comparison Studies,Case Control Study,Case Referent Studies,Case Referrent Studies,Case-Comparison Study,Case-Control Studies, Matched,Case-Control Studies, Nested,Case-Control Study,Case-Control Study, Matched,Case-Control Study, Nested,Case-Referent Study,Case-Referrent Study,Matched Case Control Studies,Matched Case-Control Study,Nested Case Control Studies,Nested Case-Control Study,Studies, Case Control,Studies, Case-Base,Studies, Case-Comparison,Studies, Case-Compeer,Studies, Case-Control,Studies, Case-Referent,Studies, Case-Referrent,Studies, Matched Case-Control,Studies, Nested Case-Control,Study, Case Control,Study, Case-Comparison,Study, Case-Control,Study, Case-Referent,Study, Case-Referrent,Study, Matched Case-Control,Study, Nested Case-Control

Related Publications

Mohamed S El Shahawy, and Mahmoud H Hemida, and Hafez A Abdel-Hafez, and Tarek Z El-Baz, and Abdel-Wahab M Lotfy, and Tarek M Emran
May 2010, Rheumatology (Oxford, England),
Mohamed S El Shahawy, and Mahmoud H Hemida, and Hafez A Abdel-Hafez, and Tarek Z El-Baz, and Abdel-Wahab M Lotfy, and Tarek M Emran
January 2015, Biomarker insights,
Mohamed S El Shahawy, and Mahmoud H Hemida, and Hafez A Abdel-Hafez, and Tarek Z El-Baz, and Abdel-Wahab M Lotfy, and Tarek M Emran
April 2013, Lupus,
Mohamed S El Shahawy, and Mahmoud H Hemida, and Hafez A Abdel-Hafez, and Tarek Z El-Baz, and Abdel-Wahab M Lotfy, and Tarek M Emran
September 2014, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association,
Mohamed S El Shahawy, and Mahmoud H Hemida, and Hafez A Abdel-Hafez, and Tarek Z El-Baz, and Abdel-Wahab M Lotfy, and Tarek M Emran
March 2008, Pediatric nephrology (Berlin, Germany),
Mohamed S El Shahawy, and Mahmoud H Hemida, and Hafez A Abdel-Hafez, and Tarek Z El-Baz, and Abdel-Wahab M Lotfy, and Tarek M Emran
October 2013, Clinica chimica acta; international journal of clinical chemistry,
Mohamed S El Shahawy, and Mahmoud H Hemida, and Hafez A Abdel-Hafez, and Tarek Z El-Baz, and Abdel-Wahab M Lotfy, and Tarek M Emran
February 2015, Lupus,
Mohamed S El Shahawy, and Mahmoud H Hemida, and Hafez A Abdel-Hafez, and Tarek Z El-Baz, and Abdel-Wahab M Lotfy, and Tarek M Emran
January 2018, Indian journal of nephrology,
Mohamed S El Shahawy, and Mahmoud H Hemida, and Hafez A Abdel-Hafez, and Tarek Z El-Baz, and Abdel-Wahab M Lotfy, and Tarek M Emran
December 2015, Lupus,
Mohamed S El Shahawy, and Mahmoud H Hemida, and Hafez A Abdel-Hafez, and Tarek Z El-Baz, and Abdel-Wahab M Lotfy, and Tarek M Emran
January 2023, Indian journal of nephrology,
Copied contents to your clipboard!